DİRENÇLİ İDİOPATİK AŞIRI AKTİF MESANELİ HASTALARDA SUBMUKOZAL BOTULİNUM TOKSİN UYGULAMASI

Year 2014, Volume: 18 Issue: 1, 20 - 24, 01.03.2014

Gökhan Temeltaş Serkan Borazan Bilal Gümüş Oktay Üçer

Abstract

İdiopatik aşırı aktif mesanesi olan ve tedavide submukozal botulinum toksin BTX uygulanan hastalardaki tedavi sonuçlarımızı değerlendirmeyi amaçladık. Ocak 2011Temmuz 2013 tarihleri arasında idiopatik aşırı aktif mesane tanısı konan ve medikal tedaviye dirençli hastalar çalışmaya dahil edildi. Hastaların mesanesine 30 ayrı noktadan submukozal olarak 200 İU BTX uygulandı. Hastalar Operasyon öncesi ve sonrası 6.ayda işeme günlüğü, sistometri, OAB-V8 sorgu formu ve ICIQ-SF sorgu formu kullanılarak değerlendirildi. Çalışmaya 12 hasta dahil edildi. Hasta yaş ortalaması 41.1±19.5 idi. Hastaların 7'si %58.3 kadın, 5'i %41.7 erkekti. Hastaların operasyon sonrası 6. ayda mesane kapasitesi ve işeme sıklığında anlamlı düzelme saptanırken, işeme sonrası rezidü idrarda da anlamlı artış meydana geldi. OAB-V8 ve ICIQ-SF skorlarında da operasyon sonrası anlamlı azalma görüldü ve bu veriler semptomların anlamlı düzeyde iyileştiğini göstermekteydi. İdiopatik aşırı aktif mesane tedavisinde submukozal olarak uygulanan BTX etkin bir tedavidir. Ancak hastalar işlem öncesi komplikasyonlar yönünden mutlaka ayrıntılı şekilde bilgilendirilmelidir

Keywords

idyopatik, aşırı aktif mesane, botox, botilinum toksin

RESULTS OF APPLICATION SUBMUCOSAL BOTULINUM TOXIN WITH REFRACTORY IDIOPATHIC OVERACTIVE BLADDER PATIENTS

Abstract

To investigate the outcomes of submucosal botilinium toxin BTX in patients with idiopathic over active bladder.Patients with idiopathic over active bladder and treatmentresistant were enrolled in this study between January 2011 and July 2013. 200 IU BTX was performed into bladder as submucosal. The patients were assessed by using voiding diary, cystometry, OAB-V8, ICIQ-SF before and after operation 6th month .12 patients were enrolled in this study. The mean of the age was 41.1±19.5. Seven of the patients were women 58.3% , five of the patients were men 41.7% . We found that there were significantly improvements of bladder capacity and pollaküria, increment of post voiding residue urine, and decrement of OAB-V8 and ICIQ-SF scores six months after the operation. Overall, findings suggested that there was significantly improvement of symptoms after the operation.Submucosal BTX might be performed in the treatment of idiopathic over active bladder effectively. However patients should be informed about the complications of BTX

Keywords

idiopathic, over active bladder, botox, botilinium toxin

References

• ) Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189: 2186- ) onabotulinumtoxinA injection: how I do it. Can J Urol 2013; 20: 6649-55. )
• Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 2008; 54: 543. )
• Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009; 65: 309. J. ) infectious diseases: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979; 1: 701–19. )
• Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919–22. )
• Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013; 111: 106-13. )
• Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al. Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int J Urol. 2009; 16:126-42. )
• Cucinella G, Saitta S, Adile B. Botox(®) for efficacy, Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012; 286: 923-9. )
• Akbal C. OAB-V8 Aşırı Aktif Mesane Sorgulama Formu Validasyon Çalışması. Üroloji Bülteni 2012; 21: 113-6. )
• SF Geçerlilik güvenilirlik çalışması. Türk Üroloji Dergisi 2004; 30: 332-8. )
• Freeman A, Kalsi V, Popat R, Gonzales G, et al. Histological changes in the urothelium and suburothelium of human overactive intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic overactivity. Eur Urol. 2008; 53: 1245- following or idiopathic detrusor
• Yazının alınma tarihi:01.02.2014 Kabül tarihi:15.02.2014 Online basım:15.02.2014